DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for brain neoplasm — screening already-approved drugs against its 71-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBrain neoplasm maps to a 71-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for brain neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
isocitrate dehydrogenase (NADP(+)) 1 (IDH1) — IDH1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ictdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6BKX · 1.65 Å · ligand ISOCITRIC ACID (ICT). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Case Reports · 2017 · 2 citations · open access
Rare case of Coexisting Meningioma and Glioma in Same Patient: A Case Report
AbstractCoexsiting different pathology brain neoplasm are quite rare in neurosurgery. However occasionally we come across such cases. This case is a female presenting with seizures and headache. Imaging revealed falcine meningioma and left frontal glioma. Single surgery for both lesions was unique and later histopathology confirmed the lesions. Postoperative period was uneventful. Patient was referred to radiotherapy for glioma. Patient is being followed up in OPD and is doing well.
The Psychiatristʼs Management of Patients With Undiagnosed Brain Neoplasm
AbstractOf 679 patients with brain neoplasms admitted to either a medical school center or a community hospital during a nine-year period, 24 had been examined by a psychiatrist before definitive diagnosis of brain neoplasm. These 24 cases were studied to evaluate the role of the psychiatrist in the management of the patients before the neoplasm was diagnosed. Such cases pose many subtle problems for psychiatrists. However, ten of the 24 patients either were sent for definitive tests by the psychiatrist with the tentative diagnosis of brain neoplasm or were triaged to other consultants to pursue that diagnosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
